KB-1165

AZD8205-hIgG1

12175

Home » AZD8205-hIgG1

Background of AZD8205-hIgG1

AZD8205 is an ADC, administered by IV infusion, that consists of a human anti-B7-H4 antibody conjugated via a cleavable linker to a topoisomerase I inhibitor (TOP1i) warhead. B7-H4 is a transmembrane protein that binds to an unknown receptor on activated T cells, inhibiting their function. It is highly expressed by a wide variety of tumors including cholangiocarcinoma (CCA) and breast, ovarian and endometrial cancers, and is associated with poor prognosis. AZD8205 specifically binds to B7-H4 expressing tumor cells and is internalized. The TOP1i warhead is released, interfering with TOP1 during DNA replication leading to transcription-mediated DNA damage and cell death.

Specifications

Catalog Number	KB-1165
Antibody Name	AZD8205-hIgG1
Isotype	Human IgG1,kappa
FC Muations	Wild Type
Target	B7H4
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA, FACS, in vivo studies
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Meric-Bernstam, Funda, Oh, Do-Youn, Naito, Yoichi, Shimizu, Toshio, Chung, Vincent, Park, Haeseong, Gaillard, Stephanie, First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors. Journal of Clinical Oncology